Trial Profile
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Jul 2023
Price :
$35
*
At a glance
- Drugs Migalastat (Primary)
- Indications Fabry's disease
- Focus Adverse reactions; Registrational
- Sponsors Amicus Therapeutics
- 01 Jul 2023 Results of pooled post hoc analysis from FACETS, ATTRACT study, open-label extension (OLE) studies (AT1001-041), AT1001-042 published in the Journal of Medical Genetics
- 05 Aug 2020 Status changed from active, no longer recruiting to completed.
- 23 Jan 2020 Planned End Date changed from 1 Oct 2019 to 1 Dec 2020.